When you say HAVE to, it is actually supported of our MOA as Dr George Perry pointed out. Also PRE SPECIFIED. When you say HAVE to, its a whole 30 day washout period and then they are all ours. No namenda payments, only bryostatin!
Now for AVXL who promoted to shareholders that their drug would be way, way better with donezepil, only to find out years later that they couldn't explain why one would bind and work and is approved while the other runs another 2 years of "precision" medicine, only to find out patients weren't included in the analysis and the drug only really works on 80% of the population anyway...I would be very interested in knowing why other Sig-1 or M-1 drugs have failed. Promising early, but when put to the test failed. This is a MAJOR study that failed.
"A Japanese drug company, Toyama Chemical, is developing an Alzheimer's drug with the same sigma-1 receptor mechanism of action as Anavex's Anavex 2-73. Two years ago, Toyama reported results from a randomized, placebo-controlled phase IIa study enrolling 370 Alzheimer's patients.
The results were disappointing: Toyama's drug, T-817MA, failed to demonstrate a statistically significant improvement in memory, cognition or activities of daily living compared to placebo during the 52 weeks of the study."
Market Data 
Markets 
AI
